Ascendis Pharma A/S Q3 FY2026 earnings call

• Strategic Vision: Management reaffirmed the 'Vision 2030' goal of generating over €5 billion in annual product revenue by 2030, supported by three drivers: existing product growth, label expansions, and new products via the Transcon platform.
• UroPath Performance: The drug is available in more than 40 countries. In the U.S., there are an estimated 70,000–90,000 potential candidates, with over 90% still untreated. A national disease awareness campaign launched in September aims to empower patients to seek treatment.
• UroVel Progress: Enrollment reached ~340 patients in the U.S. by October, with >80% approved for reimbursement. The company received a positive CHMP opinion in Europe, with a Commission decision expected before year-end and a planned German launch in Q1 2027.
• R&D Pipeline Expansion: Multiple trials are ongoing, including dose escalation for UroPath, expansion of UroVel indications (including infants and hypochondroplasia), and combination therapies. Early data showed Transcon-CMP improved skeletal proportionality and spinal canal dimensions.
• Transcon Platform & New Therapeutic Areas: Ascendis is expanding beyond endocrine rare diseases into metabolic and cardiovascular areas. They aim to advance at least one new product into clinical development annually, with disclosures on the new therapeutic area expected in early 2027.
• Financial Health: The company is self-sustaining with increasing operating cash flow. Q3 operating profit was €125 million (Non-IFRS €156 million, margin 42%). Cash position ended Q3 at €964 million.

Total product revenue was €366 million, up 89% year-over-year and €51 million sequentially. The breakdown by segment is as follows:

• UroPath (Hyperparathyroidism): Revenue of €291 million, representing approximately 79.5% of total product revenue. This reflects a 103% year-over-year increase and a €39 million sequential rise, driven by consistent new patient demand in the U.S. and continued international growth.
• Skytropha (Growth Disorders): Revenue of €59 million, representing approximately 16.1% of total product revenue. This shows steady performance with a €4 million sequential increase.
• UroVel (Achondroplasia): Revenue of €16 million, representing approximately 4.4% of total product revenue. This represents a doubling from the previous quarter's €8 million, reflecting steady enrollment and high reimbursement approval rates in the U.S.

• Q4 2026 Outlook: Expectation of growth consistent with prior quarters for UroPath in both U.S. and ex-U.S. markets. Skytropha revenue is expected to remain relatively stable in the U.S. UroVel demand and approval trends are expected to continue growing in the U.S., with additional growth from EU launches and international availability.
• Full Year 2026 Cash Flow: Revised upward expectation for full-year 2026 operating cash flow to be at least €600 million.
• Long-Term Targets: Reinforced goals of >€5 billion revenue by 2030 and €10 billion by 2035, driven by label expansions, global commercialization, and new Transcon-based products.

• Regulatory and Approval Delays: Success of long-term growth depends on receiving European Commission decisions for UroVel and approvals for new indications/trials within expected timelines.
• Commercial Execution Risks: International growth is slower than the U.S. due to reliance on name-patient programs rather than full commercial availability; acceleration depends on achieving full commercial status in 15+ new markets in 2027.
• Competitive Landscape: Potential impact from new oral drugs or competitors in achondroplasia, though management emphasizes safety and efficacy advantages of their sustained-release platform.
• Pipeline Uncertainty: Development of new therapeutic areas and products carries inherent R&D risks, with no guarantees that new chemical entities will achieve commercial success.

Q: When will Ascendis disclose the new therapeutic area outside of endocrinology, and will blockbusters come from internal development or M&A? / A: CEO Jan Mikkelsen stated that details on the new therapeutic area would be disclosed in the coming year, likely early 2027. He emphasized that the majority of new products will be developed internally using the Transcon platform, but the company remains open to analyzing 1-2 external assets that synergize with their pipeline. The focus is on building sustainability through internal innovation while maintaining flexibility for strategic acquisitions.